Forward catalyst · AZN

rezvilutamide

Sponsor AZN · listed as AZN

READOUT Phase 3 Confidence: medium Source: clinicaltrials

rezvilutamide is a clinical-stage drug asset sponsored by AZN, listed as AZN. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Mar 2027 (month precision, medium confidence), tied to trial NCT07241416. The asset is in Phase 3 and currently recruiting, studied in Metastatic Hormone-sensitive Prostate Cancer (mHSPC). It appears across 2 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT

Expected date2027-03-31

As disclosedMar 2027

Date precisionmonth

Confidencemedium

Verify at source →

Trial & sponsor

Trial (NCT)NCT07241416

PhasePHASE3

StatusRECRUITING

Lead sponsorJiangsu HengRui Medicine Co., Ltd.

Listed asAZN

Condition(s)Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 → More AZN catalysts